Analysis of Videodermatoscopic Parameters of Ocular, Periocular, Conjunctival and Palpebral Neoformations
1 other identifier
observational
300
1 country
1
Brief Summary
ANALYSIS OF VIDEODERMATOSCOPIC PARAMETERS OF OCULAR, PERIOCULAR, CONJUNCTIVAL AND PALPEBRAL NEOFORMATIONS
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 15, 2021
CompletedFirst Submitted
Initial submission to the registry
November 28, 2024
CompletedFirst Posted
Study publicly available on registry
December 4, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 15, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 15, 2030
December 5, 2024
October 1, 2024
5.5 years
November 28, 2024
December 3, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
features that could indicate their benign or malignant nature
clinical and dermoscopic characteristics of periocular and ocular lesions
from enrollment to the end of 2026
Eligibility Criteria
patients presented to the Videodermatoscopy Outpatient Clinic of the O.U. Dermatology of the S. Orsola-Malpighi General Hospital
You may qualify if:
- patients who had been diagnosed with one of the following conditions in the ocular and periocular region: common melanocytic nevus, melanosis, seborrheic keratosis, viral wart, angioma and angiokeratoma, apocrine hydrocystoma, xanthelasma, steatocystoma, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, melanoma.
You may not qualify if:
- Patients who presented with one of the following conditions were excluded from the study: concomitant inflammatory processes, including blepharitis, chalazion, pterygium, pinguecula), coexistence of multiple, periocular or ocular lesions, diagnosis of syndromic diseases related to a major risk for cutaneous neoformations.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, 40138, Italy
Study Officials
- PRINCIPAL INVESTIGATOR
Sabina Vaccari, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 28, 2024
First Posted
December 4, 2024
Study Start
June 15, 2021
Primary Completion (Estimated)
December 15, 2026
Study Completion (Estimated)
December 15, 2030
Last Updated
December 5, 2024
Record last verified: 2024-10